Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OBSV NASDAQ:PTIX NYSEAMERICAN:SVT NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOBSVObsEva$0.00$0.08▼$2.14$39K0.688.94 million shs222 shsPTIXAtrinsic$3.48+0.9%$3.90$2.35▼$15.54$2.06M0.34576,772 shs56,194 shsSVTServotronics$46.94$40.34$9.67▼$47.48$120.17M1.4911,985 shsN/ATRAWTraws Pharma$1.61+1.6%$1.48$0.97▼$19.44$8.92M1.46449,592 shs37,203 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOBSVObsEva-75.00%-75.00%-75.00%-75.00%-75.00%PTIXAtrinsic-0.86%-9.92%+1.77%+2.72%-65.82%SVTServotronics0.00%0.00%+0.09%+357.95%+311.39%TRAWTraws Pharma+6.76%+1.94%-3.07%-20.20%+157,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/APTIXAtrinsic0.5206 of 5 stars0.02.00.00.03.31.70.0SVTServotronicsN/AN/AN/AN/AN/AN/AN/AN/ATRAWTraws Pharma0.8066 of 5 stars0.05.00.00.02.20.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOBSVObsEva 0.00N/AN/AN/APTIXAtrinsic 0.00N/AN/AN/ASVTServotronics 0.00N/AN/AN/ATRAWTraws Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/APTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ASVTServotronics$44.92M2.68$0.07 per share658.77$9.20 per share5.10TRAWTraws Pharma$230K38.80N/AN/A($8.66) per share-0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APTIXAtrinsic-$5.53M-$13.11N/A∞N/AN/A-860.52%-354.19%8/12/2025 (Estimated)SVTServotronics-$1.62M$0.05N/A∞N/A-2.32%-1.23%-0.82%8/6/2025 (Estimated)TRAWTraws Pharma-$166.52M-$32.81N/AN/AN/A-15,245.81%N/A-193.21%8/21/2025 (Estimated)Latest PTIX, SVT, TRAW, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TRAWTraws Pharma-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million5/13/2025Q1 2025PTIXAtrinsicN/A-$2.75N/A-$2.75N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOBSVObsEvaN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ASVTServotronicsN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOBSVObsEvaN/A0.610.61PTIXAtrinsicN/A0.860.86SVTServotronicsN/A3.461.65TRAWTraws PharmaN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOBSVObsEva17.52%PTIXAtrinsic7.97%SVTServotronics24.77%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipOBSVObsEva14.40%PTIXAtrinsic35.00%SVTServotronics33.90%TRAWTraws Pharma13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOBSVObsEva5077.97 million66.74 millionNot OptionablePTIXAtrinsic2590,000383,000Not OptionableSVTServotronics2702.56 million1.69 millionNot OptionableTRAWTraws Pharma175.56 million4.81 millionOptionablePTIX, SVT, TRAW, and OBSV HeadlinesRecent News About These CompaniesTRAW - Traws Pharma Inc Sustainability - MorningstarJuly 16 at 4:38 PM | morningstar.comMCooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws PharmaJuly 8, 2025 | msn.comTraws Pharma announces chief financial officer transitionJuly 5, 2025 | uk.investing.comTraws Pharma, Inc. (TRAW) Income Statement - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comTraws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory SubmissionsJune 30, 2025 | finanznachrichten.deTraws Pharma Submits Phase 2 Protocols for Tivoxavir Marboxil and Ratutrelvir to HREC and FDAJune 30, 2025 | quiverquant.comQTraws Pharma Advances Antiviral Pipeline with Multiple Regulatory SubmissionsJune 30, 2025 | globenewswire.comTraws Pharma Announces Promising Clinical Data for Rigosertib in Rare CancerJune 5, 2025 | msn.comTraws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug RigosertibJune 3, 2025 | globenewswire.comTraws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic PreparednessMay 27, 2025 | globenewswire.comTraws Pharma Unveils New Strategic Antiviral FocusMay 19, 2025 | tipranks.comTraws Pharma Highlights Q1 2025 Financial Progress and Antiviral DevelopmentsMay 18, 2025 | msn.comTraws Pharma Reports First Quarter 2025 Results and Business HighlightsMay 15, 2025 | globenewswire.comTraws Pharma Appoints New Chairman Amid Leadership ChangesApril 18, 2025 | tipranks.comThe Escalator: HHS, Spectrum Science, Alvotech and moreApril 3, 2025 | mmm-online.comMTraws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID ProgramsApril 2, 2025 | msn.comTraws Pharma reports FY24 EPS ($35.21)April 1, 2025 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Virtual Investor Event TranscriptApril 1, 2025 | seekingalpha.comTraws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | finanznachrichten.deTraws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTIX, SVT, TRAW, and OBSV Company DescriptionsObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Atrinsic NASDAQ:PTIX$3.48 +0.03 (+0.87%) As of 12:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Servotronics NYSEAMERICAN:SVT$46.94 0.00 (0.00%) As of 07/1/2025Servotronics, Inc. designs, manufactures, and markets servo-control components and other technology products for aerospace, military, and medical applications in the United States and internationally. It offers high-performance servo valves, including torque motor, hydraulic, and pneumatic valves. The company offers its products to products are sold to commercial aerospace, government, medical, and industrial markets. The company was incorporated in 1959 and is headquartered in Elma, New York.Traws Pharma NASDAQ:TRAW$1.60 +0.03 (+1.58%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
